Director at Protagonist Therapeutics (PTGX) sells shares after exercising options

Rhea-AI Filing Summary

Protagonist Therapeutics director William D. Waddill exercised stock options and sold shares in a coordinated transaction. He exercised 9,000 shares of Common Stock at $11.80 per share, then sold 9,000 shares in an open-market sale at $99.64 per share.

After these transactions, he directly holds 7,825 shares of Common Stock and 3,000 stock options remain outstanding, with the options expiring on June 6, 2029. The filing notes the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 9,000 shares ($896,760)

Net Sell 3 txns

Insider Waddill William D.

Role null

Sold 9,000 shs ($897K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	9,000	$0.00	--
Exercise	Common Stock	9,000	$11.80	$106K
Sale	Common Stock	9,000	$99.64	$897K

Holdings After Transaction: Stock Option (right to buy) — 3,000 shares (Direct, null); Common Stock — 16,825 shares (Direct, null)

Footnotes (1)

1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. These stock options are fully vested.

Key Figures

Shares sold: 9,000 shares Sale price: $99.64 per share Options exercised: 9,000 shares +5 more

8 metrics

Shares sold 9,000 shares Common Stock sold in open-market transaction

Sale price $99.64 per share Price for 9,000 Common Stock shares sold

Options exercised 9,000 shares Common Stock acquired via option exercise

Exercise price $11.80 per share Stock option exercise price for 9,000 shares

Shares held after 7,825 shares Common Stock directly owned following transactions

Options remaining 3,000 options Stock options outstanding after exercise

10b5-1 plan adoption date February 27, 2026 Date reporting person adopted Rule 10b5-1 plan

Option expiration June 6, 2029 Expiration date of remaining stock options

Key Terms

Rule 10b5-1 plan, open-market sale, Stock Option (right to buy), fully vested

4 terms

Rule 10b5-1 plan regulatory

"transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action: "open-market sale" for 9,000 Common Stock shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)" with underlying Common Stock"

fully vested financial

"These stock options are fully vested."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waddill William D.

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		M(1)		9,000	A	$11.8	16,825	D
Common Stock	05/29/2026		S		9,000	D	$99.64	7,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$11.8	05/29/2026		M			9,000	(2)	06/06/2029	Common Stock	9,000	$0.00	3,000	D

Explanation of Responses:

1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026.

2. These stock options are fully vested.

	/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PTGX director William D. Waddill report?

Director William D. Waddill reported exercising stock options and selling shares of Protagonist Therapeutics common stock. He exercised 9,000 options and sold 9,000 shares in an open-market transaction, reflecting a typical exercise-and-sell pattern for equity compensation rather than a standalone open-market purchase.

How many Protagonist Therapeutics (PTGX) shares did the director sell and at what price?

Waddill sold 9,000 shares of Protagonist Therapeutics common stock at an average price of $99.64 per share. The transaction was coded as an open-market or private sale, indicating an executed disposition of shares rather than a grant or internal reclassification transaction.

What stock options did the PTGX director exercise in this Form 4 filing?

He exercised stock options covering 9,000 shares of Protagonist Therapeutics common stock at an exercise price of $11.80 per share. These options were fully vested, and 3,000 options remain outstanding after the transaction, with an expiration date of June 6, 2029.

How many Protagonist Therapeutics shares does the director hold after the reported transactions?

Following the transactions, Waddill directly holds 7,825 shares of Protagonist Therapeutics common stock. In addition, 3,000 stock options remain outstanding, providing further potential equity exposure if exercised before their stated expiration date in June 2029.

Were the PTGX insider transactions made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on February 27, 2026. Such pre-arranged plans schedule trades in advance, which can reduce the significance of trade timing as a signal of the insider’s current market view.

What does the Form 4 reveal about remaining PTGX stock options for the director?

After exercising 9,000 options, the director has 3,000 stock options still outstanding. These options are fully vested and carry a stated expiration date of June 6, 2029, giving him additional potential to acquire Protagonist Therapeutics shares in the future if he elects to exercise.